Granulocyte-macrophage colony stimulating factor + Nimustine + Temozolomide

This is a combination therapy involving three distinct components: granulocyte-macrophage colony stimulating factor (GM-CSF), nimustine, and temozolomide. It appears to be a therapeutic approach primarily considered for the treatment of brain tumors, particularly malignant gliomas. **Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)**: GM-CSF is a growth factor that stimulates the production of white blood cells, particularly granulocytes and macrophages. It is used to enhance immune function and prevent infection in patients undergoing myelosuppressive therapy. Available forms include sargramostim (Leukine) and molgramostim. GM-CSF works by increasing hematopoietic cell counts, enhancing immune function, helping the body make more white blood cells, and protecting against infection during chemotherapy. **Temozolomide**: Temozolomide (brand name Temodar) is an alkylating agent used to treat brain tumors, particularly glioblastoma and anaplastic astrocytoma. It is available in oral capsule form and as an injectable solution. Temozolomide works by stopping the ability of cancer cells to grow and divide, and by slowing or stopping cancer tumors from growing, acting as a chemotherapy agent that kills cells. **Nimustine**: Nimustine is a nitrosourea compound used as an antineoplastic agent, primarily for treating brain tumors and other malignancies. Nitrosoureas are a class of alkylating agents. **Rationale for Combination**: The combination aims to provide comprehensive anti-cancer effects while managing side effects. Temozolomide and nimustine provide direct cytotoxic and antineoplastic effects against tumor cells, with both acting as alkylating agents. GM-CSF is included to counteract the myelosuppressive effects of these chemotherapy agents, helping to maintain white blood cell counts and reduce the risk of infection, particularly chemotherapy-induced neutropenia, which is a common concern with cytotoxic treatments.